Publication summary

Showing 9 of 0 results

• Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Gastric/Esophageal cancer
• From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Artificial intelligence
• Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Small cell lung cancer
• Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Non-small cell lung cancer
• Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Machine learning
  • Metastatic breast cancer
  • Artificial intelligence
• Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Non-small cell lung cancer
  • Artificial intelligence
• Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Ovarian cancer
• Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Treatment patterns
  • Prostate cancer
• Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Comparative effectiveness
  • Non-small cell lung cancer
  • Artificial intelligence